First Mercantile Trust Co Lowers stake in Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : First Mercantile Trust Co reduced its stake in Boston Scientific Corporation by 2.53% during the most recent quarter end. The investment management company now holds a total of 57,750 shares of Boston Scientific Corporation which is valued at $1,355,970 after selling 1,500 shares in Boston Scientific Corporation , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Boston Scientific Corporation makes up approximately 0.18% of First Mercantile Trust Co’s portfolio.

Other Hedge Funds, Including , Exxonmobil Investment Management Inc Tx reduced its stake in BSX by selling 3,779 shares or 1.08% in the most recent quarter. The Hedge Fund company now holds 347,446 shares of BSX which is valued at $8,158,032. Boston Scientific Corporation makes up approx 0.17% of Exxonmobil Investment Management Inc Tx’s portfolio.Independent Portfolio Consultants reduced its stake in BSX by selling 1,445 shares or 14.52% in the most recent quarter. The Hedge Fund company now holds 8,505 shares of BSX which is valued at $199,272. Boston Scientific Corporation makes up approx 0.06% of Independent Portfolio Consultants’s portfolio.Chevy Chase Trust Holdings reduced its stake in BSX by selling 23,705 shares or 2.04% in the most recent quarter. The Hedge Fund company now holds 1,136,823 shares of BSX which is valued at $26,635,763. Boston Scientific Corporation makes up approx 0.15% of Chevy Chase Trust Holdings’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in BSX by selling 21,531 shares or 22.54% in the most recent quarter. The Hedge Fund company now holds 73,993 shares of BSX which is valued at $1,733,656. Boston Scientific Corporation makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio.Washington Trust Bank reduced its stake in BSX by selling 37 shares or 19.68% in the most recent quarter. The Hedge Fund company now holds 151 shares of BSX which is valued at $3,538.

Boston Scientific Corporation (BSX) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $23.58 and reached the intraday high at $23.65. The bulls started the profit booking and pushed the shares to intraday low of $23.37. The trading session was marked by a volume range of 51,53,714 shares exchanging hands. The 52-week high of the shares is $24.79 and the 52-week low is $15.67. The market cap of the company stands at $31,950 M and there are 1,36,07,43,300 shares in public circulation.

On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Boston Scientific Corporation was Upgraded by Argus to ” Buy” on Sep 1, 2016. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.